Literature DB >> 17895822

Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease.

Christopher I Zoumalan1, Kimberly P Cockerham, Roger E Turbin, Nicholas J Volpe, Michael Kazim, Raymond S Douglas, Steven E Feldon.   

Abstract

Thyroid Eye Disease (TED, Graves ophthalmopathy, thyroid ophthalmopathy) is the most common cause of orbital inflammation and proptosis in adults. There is no agreement on its management although corticosteroids and external beam orbital radiation (XRT) have traditionally been believed to provide benefit in active inflammation. Our review of the published literature in English disclosed an overall corticosteroid-mediated treatment response of 66.9% in a total of 834 treated patients who had moderate or severe TED. Intravenous corticosteroids used in repeated weekly pulses were more effective (overall favorable response = 74.6%, n = 177) and had fewer side effects than daily oral corticosteroids (overall favorable response = 55.5%, n = 265). A combination of corticosteroid and radiation therapy seemed to be more effective than corticosteroids alone. Our conclusions are tempered by a notable lack of standardization within and between study designs, treatment protocols, and outcome measures. Accordingly, the North American Neuro-Ophthalmology Society (NANOS), American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) and the Orbital Society, in conjunction with Neuro-Ophthalmology Research and Development Consortium (NORDIC), will investigate the design and funding of a multi-center controlled trial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17895822     DOI: 10.1097/WNO.0b013e31814a5ef8

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  9 in total

1.  Ocular changes and approaches of ophthalmopathy in basedow - graves- parry- flajani disease.

Authors:  George Saraci; Anamaria Treta
Journal:  Maedica (Buchar)       Date:  2011-04

2.  Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.

Authors:  Eric B Suhler; Lyndell L Lim; Robert M Beardsley; Tracy R Giles; Sirichai Pasadhika; Shelly T Lee; Alexandre de Saint Sardos; Nicholas J Butler; Justine R Smith; James T Rosenbaum
Journal:  JAMA Ophthalmol       Date:  2014-05       Impact factor: 7.389

Review 3.  Thyroid eye disease: towards an evidence base for treatment in the 21st century.

Authors:  Erin F Gillespie; Terry J Smith; Raymond S Douglas
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

Review 4.  Rituximab for thyroid-associated ophthalmopathy.

Authors:  Swan Kang; Shirin Hamed Azzam; Neda Minakaran; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2022-06-16

Review 5.  The eye and thyroid disease.

Authors:  Ajay E Kuriyan; Richard P Phipps; Steven E Feldon
Journal:  Curr Opin Ophthalmol       Date:  2008-11       Impact factor: 3.761

6.  Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.

Authors:  Dinesh Khanna; Kelvin K L Chong; Nikoo F Afifiyan; Catherine J Hwang; Diana K Lee; Helene Chokron Garneau; Robert A Goldberg; Christine H Darwin; Terry J Smith; Raymond S Douglas
Journal:  Ophthalmology       Date:  2009-10-08       Impact factor: 12.079

7.  Reduction of orbital inflammation following decompression for thyroid-related orbitopathy.

Authors:  Sang-Rog Oh; Jonathan D Tung; Ayelet Priel; Leah Levi; David B Granet; Bobby S Korn; Don O Kikkawa
Journal:  Biomed Res Int       Date:  2013-06-18       Impact factor: 3.411

Review 8.  Will mesenchymal stem cells be future directions for treating radiation-induced skin injury?

Authors:  Zhuoqun Fang; Penghong Chen; Shijie Tang; Aizhen Chen; Chaoyu Zhang; Guohao Peng; Ming Li; Xiaosong Chen
Journal:  Stem Cell Res Ther       Date:  2021-03-12       Impact factor: 6.832

9.  Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2016-04-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.